University of Louisville
Journal of Respiratory Infections
ORIGINAL RESEARCH

Comparison of Mortality and Therapy in Community Acquired
Pneumonia
Gina Maki1*, Nikhath Zeeshan1, Yuan Xin 1, Daniela Moreno1, Anthony D Harris2, Steven J Lawrence3, Andrew Masica4, Lois
Lamerato1, Marcus Zervos1,5

Abstract
Background: Community associated pneumonia (CAP) is one the most common causes of hospital
admissions, exceeding more than one million per year in the United States, contributing to 3.4% of
inpatient mortality. Our objective was to compare 30-day mortality using therapies recommended for
treatment of CAP.
Methods: A multicenter retrospective analysis from four different hospitals was assessed from 2008
to 2013. The data was obtained from electronic medical records which included more than 70,000
patients. CAP patients were identified using discharge diagnostic codes during the years 2008-2013,
as well as receiving therapy with ceftriaxone and azithromycin or a respiratory fluoroquinolone.
Demographic data, antibiotic therapy, and Charlson comorbidity score was obtained to compare the
study groups.
Results: A total of 21,800 patients met the inclusion criteria for CAP. 1,740 patients were excluded
as they received both beta-lactams and fluoroquinolones. The study included 20,600 patients.
11,201 patients (55.84%) received ceftriaxone with azithromycin, and 8,859 (44.16%) received
fluoroquinolone therapy. The mortality rate for patients who received fluoroquinolone therapy was
lower compared to the patients who received ceftriaxone plus azithromycin (3.56% vs 6.71%, p-value
<0.001).
Conclusions: Our study showed statistically significant lower 30-day mortality using fluoroquinolone
therapy compared to ceftriaxone plus azithromycin for treatment of CAP. Prospective blinded
randomized control trials would be needed to support this evidence.
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Introduction
Pneumonia is one the most common causes of hospital
admissions exceeding more than one-million cases per year,
contributing to 3.4% of inpatient mortality [1,2]. There are
several studies conducted to compare different antibiotics for
the treatment of community acquired pneumonia, however
there are limited data from large trials comparing ceftriaxone
plus azithromycin to fluoroquinolone therapy for inpatient
treatment of CAP. The current IDSA guidelines published in
2007 recommend treatment of CAP in non-ICU patient with
fluoroquinolone alone or beta-lactam plus macrolide [3].
Arnold and colleagues [4] compared treatment of pneumonia
with current guidelines to non-adherence to guidelines. The
study concluded that adhering to the guidelines decreased
the mortality rate, length of hospital stay, and time to clinical
stability. Wang and colleagues compared fluoroquinolone
based therapy to penicillin based therapy in the treatment of
community acquired pneumonia in an outpatient setting [5].
The study concluded that the treatment failure rates were less
in fluoroquinolone based therapy compared to penicillin based
therapy, and no difference in hospitalizations, emergency visits

or 30-day mortality. A recent cluster-randomized, crossover
trial concluded that beta-lactam monotherapy was noninferior to the beta-lactam plus macrolide or fluoroquinolone
monotherapy [6] .
Better knowledge of optimal treatment is critical to improve
outcomes. Our study is unique in comparing 30-day all-cause
mortality benefit using ceftriaxone plus azithromycin to
fluoroquinolones in a large multicenter cohort for treatment of
CAP.

Methods
We conducted a retrospective review from January 2008 to
December 2012 including inpatients 18 years of age or older who
were hospitalized with the diagnosis of community acquired
pneumonia based on ICD-9 discharge diagnosis. Participating
centers included four large health care institutions located in
Maryland, Michigan, Missouri, and Texas. Information about
patients’ sex, age, race, discharge diagnosis, cultured organism,
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hospital length of stay, readmission status, and mortality within
30 days was collected from each of the four hospitals’ electronic
medical records (EMR). Information was obtained from each
participating centers’ EMR which was then entered into a
single database. This database included approximately 70,000
patients. Data was de-identified and coded using explicit data
specifications and uploaded into one large database. The study
protocol was approved by the institutional review board (IRB)
at each participating institution. Teleconferences, enrollments
reports, and data audits were conducted between the four study
sites to ensure uniform data collection.
All hospitalized patients in these hospitals between January
1, 2008 and December 30, 2012 with a discharge diagnosis
of pneumonia were identified. Patients were included in the
present study if: 1) They were aged ≥18 years; 2) They had
received either ceftriaxone plus azithromycin, levofloxacin,
or moxifloxacin for the duration of the hospitalization with no
other antibiotics administered. Exclusion criteria included: 1)
Patients who received other antimicrobial agents; 2) Patients
with diagnosis of pneumonia with no information on therapy; 3)
Patients who received both therapies. The primary outcome of
the study was 30-day all-cause mortality. In hospital mortality
was used as a marker for 30-day mortality, as our database
was unable to assess 30-day mortality. The patients’ severity of
comorbidities was assessed using Charlson comorbidity index.
Statistical Methods
Univariate statistical analysis was used to test the association
of demographic and clinical characteristics with all-cause
discharge mortality. Categorical variables were analyzed using
the Chi-squared test or Fisher’s exact test. Continuous variables
were analyzed using an unpaired t-test. All variables with a
p-value < 0.05 in the univariate analysis were included into the
multivariate logistic regression. The stepwise selection method
was performed to generate the final model (P≤0.05 required
for variable entry, P≤0.10 required for variable removal). All
p-values were two-sided. Analyses were performed by using SAS
9.4.

Results
A total of 21,800 patients met our inclusion criteria for CAP,
however 1,740 patients were excluded as they received both
beta-lactams and fluoroquinolones. The study included 20,600
patients. 11,201 patients (55.84%) received ceftriaxone with
azithromycin, and 8,859 (44.16%) received fluoroquinolone
therapy. Demographic and clinical characteristics of patients
are shown in Table 1. The mortality rate for patients who
received fluoroquinolone therapy was lower compared to the
patients who received ceftriaxone plus azithromycin (3.56% vs
6.71%, p-value <0.001).

Discussion
Our study demonstrated that the use of fluoroquinolone therapy
for treatment of CAP decreased 30-day all-cause mortality
compared to ceftriaxone plus azithromycin. Despite high
comorbidity index in the cohort treated with fluoroquinolones,
those treated with fluoroquinolones had better outcomes
than those treated with ceftriaxone plus azithromycin. Our
study is unique in several ways. First, the large sample size

of this study strengthens the analysis as well as significantly
different variables. Second, there have been limited studies
conducted to compare ceftriaxone plus azithromycin to
fluoroquinolone therapy with respect to mortality. The present
study only included patients treated with these agents. Third,
the data is collected from four different hospitals which are
located in various locations throughout United States. Despite
various geographic locations of the hospitals with different
antibiograms, fluoroquinolones had mortality benefit over
ceftriaxone plus azithromycin. Our study results are disconcordant with the meta-analysis of randomized controlled
trials by Vardakas et al [7]. Their interpretation did reveal that
fluoroquinolone therapy has a higher success rate in treatment
of pneumonia compared to beta-lactam therapy with and
without macrolides, however the data showed that there was no
mortality benefit with fluoroquinolones. One of the possibilities
several studies favor fluoroquinolone therapy is that there is
different spectrum of coverage of fluoroquinolones including
MSSA, gram-negative coverage including anti-pseudomonal
activity for some agents such as levofloxacin, as well as
atypical coverage [8]. Another factor may be the emergence of
Streptococcus pneumonia which are resistant to macrolides.
Multiple studies favor monotherapy with a fluoroquinolone over
combination therapy. Querol-Ribelles et al. in a prospective
observational cohort study showed improved mortality in
patients treated with levofloxacin compared to those treated
with combination therapy of ceftriaxone plus clarithromycin
[9]. Another meta-analysis of randomized controlled trials by
Raz-Pasteur et al. did not reveal a mortality benefit between
monotherapy and combination therapy with a beta-lactam;
however, the study was significant for decreased failure rates
of therapy and treatment discontinuation in those receiving
monotherapy with a fluoroquinolone [10]. Limitations of the
present study include that it was a retrospective observational
study with information gathered using only electronic medical
records. The immune status of patients were unable to be
obtained. Pneumonia severity index and CURB-65 scores,
which are markers of disease severity, were unable to be
obtained. Without calculating these scores, we cannot rule out
the possibility of confounding by indication of the use of therapy
based on disease severity. Many patients with CAP have no
organism identified further limiting comparison of outcomes
between the groups. Another limitation is that it is possible that
activity against organisms isolated were different in one group
versus another, which was not evaluated in this study. Finally,
mortality during hospitalization was obtained, we did not have
information on 30-day mortality, thus in hospital mortality was
used as a marker for 30-day mortality.

Conclusions
Our study showed statistically significant lower 30-day mortality
using fluoroquinolone therapy compared to ceftriaxone plus
azithromycin for treatment of community acquired pneumonia.
Further randomized controlled trials would be needed to
support this evidence.
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Table 1 Demographics and clinical characteristics and outcomes of patients admitted to the hospital with CAP
Patient characteristics
Total patients
Age
Mean Age
>65 years
<65 years
Gender
Male
Female
Race
White
Black
Hispanic
Asian
Other
Unknown
Comorbidities
HIV
DM
Transplant
Asthma
COPD
Sickle Cell
CAD
Asplenia
CKD
Heart Failure
Cancer
Hypertension
Charlson score
Mortality

Fluoroquinolone therapy n (%) Ceftriaxone plus azithromycin n (%) p-value
8859 (44.16)
11201(55.84)
64.2764 ± 17.1823
4266 (48.15)
4593 (51.85)

59.5046 ± 18.3095
6660 (59.46)
4541 (40.84)

<0.001
<0.001
<0.001

4172 (47.09)
4687 (52.91)

5469 (48.83)
5732 (51.17)

0.0147

5369 (60.61)
2476 (27.95)
738 (8.33)
137 (1.55)
97 (1.09)
42 (0.47)

5263 (46.99)
4615 (41.20)
655 (5.85)
141 (1.26)
161 (1.44)
366 (3.27)

264 (2.98)
3104 (35.04)
315 (3.56)
1443 (16.29)
2701 (30.49)
95 (1.07)
2885 (32.57)
1061 (11.98)
1076 (12.15)
2693 (30.40)
1633 (18.43)
6514 (73.53)
4.0227 ± 2.2527
315 (3.56%)

857 (7.65)
3542 (31.62)
450 (4.02)
1974 (17.62)
2868 (25.60)
140 (1.25)
3056 (27.28)
982 (8.77)
1239 (11.06)
3052 (27.25)
1785 (15.94)
7518 (67.12)
3.5011 ± 2.2537
752 (6.71%)
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